PRRT

You have access
Practical Considerations for Implementation of ¹⁷⁷Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Diane K. Soulek, Nic J. Mastascusa, Molly E. Martin and Stephen A. Graves

Journal of Nuclear Medicine Technology June 14, 2022, jnmt.122.263813; DOI: https://doi.org/10.2967/jnmt.122.263813
You have access
Technical Aspects and Administration Methods of ¹⁷⁷Lu-DOTATATE for Nuclear Medicine Technologists
Audrey B. Davis, Melanie H. Pietryka and Susan Passalaqua

Journal of Nuclear Medicine Technology December 1, 2019, 47 (4) 288-291; DOI: https://doi.org/10.2967/jnmt.118.221846
You have access
Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of ⁶⁸Ga/¹⁷⁷Lu-DOTATATE with Improvement of Vision
Rahul V. Parghane and Sandip Basu

Journal of Nuclear Medicine Technology June 1, 2019, 47 (2) 171-172; DOI: https://doi.org/10.2967/jnmt.118.217455
You have access
Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted ¹⁷⁷Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
Sandip Basu and Rohit Ranade

Journal of Nuclear Medicine Technology June 1, 2016, 44 (2) 85-87; DOI: https://doi.org/10.2967/jnmt.115.163527

Main menu